Clinical trials: Overweight or Obese
Overweight, Obesity
Weight and Metabolic Management Study
The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them.
- Conditions
- Overweight, Obesity, Weight Maintenance
- Trial name
- WMMS (NCT07789223)
- Testing
- elénzia CONTROL®
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Elenzia
Obesity, Childhood, Pediatric Obesity
Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents & Providers
The US Preventive Services Task Force (USPSTF) recommends that providers screen children aged 6 years and older for obesity and offer or refer them to a comprehensive behavioral intervention (≥26 hours over a period of up to 12…
- Conditions
- Obesity, Childhood, Pediatric Obesity, Childhood Obesity, Adolescent Obesity
- Trial name
- TEAM UP (NCT03843424)
- Testing
- eSOC program, FBT program
- Where
- 7 sites in United States
- Volunteers
- 1,460 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Overweight or Obesity
Examination of Circumferential Reduction
The rationale for the selection of Outcome Measures is the compliance with FDA regulations as pertain to medical devices with a moderate level of risk of hazard leading to harm of the patient; firstly, the safety of the device in…
- Trial name
- NCT04451824
- Testing
- CL-100
- Where
- 3 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Contour Research
Obesity, Leprosy
Effect of Weight and/or Obesity on Dapsone Drug Concentrations
This study will find how weight affects the dosing of a drug called dapsone. Currently, the amount of dapsone a patient receives is the same regardless of the patient's weight.
- Conditions
- Obesity, Leprosy, Tuberculosis
- Trial name
- NCT01165840
- Testing
- Dapsone
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Obesity, Overweight
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM.
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Trial name
- NCT07654374
- Testing
- aleniglipron
- Where
- 74 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection
- Trial name
- NCT07842640
- Testing
- ASC35 Injection B, for subcutaneous use, Tirzepatide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Overweight and Obesity
EXerCise wEight Loss
The overall aim of this study is to investigate the effects of home-based resistance exercise programme on changes in body composition and strength during weight loss, in people living with obesity or overweight.
- Trial name
- EXCEL (NCT05702840)
- Testing
- Resistance exercise training + weight loss group, Weight loss only group (WL)
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Cardiovascular Diseases
Effect of Exercise or Metformin on Nocturnal Blood Pressure and Other Risk Factors for CVD Among Obese Adolescents
The objective is to, among obese adolescents, study impact of regular physical activity or metformin therapy on nocturnal blood pressure and related cardiovascular disease risk factors.
- Trial name
- NCT00889876
- Testing
- Metformin group, Exercise
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Maria Sandberg Westerstahl
Obesity, Weight Loss
Obesity Treatment With LCD in Primary Health Care
The aim of this study is to evaluate if an internet-based CBT (Cognitive Behavioral Therapy) programme for weight stability after LCD (Low Calorie diet) treatment for obesity, can reduce weight gain and improve weight stability…
- Trial name
- LCD-KBT (NCT01608191)
- Testing
- CBT follow up
- Where
- Sweden
- Volunteers
- 174 people
- Sponsor
- Örebro County Council
Diabetes
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
Type 1 Diabetes (T1DM) is a disease characterised by immune mediated destruction of the insulin-producing pancreatic beta cells. Overtime, obvious insulin deficiency develops which requires insulin therapy.
- Trial name
- NCT06762314
- Testing
- Insulin, Semaglutide, Empagliflozin
- Where
- Egypt
- Volunteers
- 114 people
- Sponsor
- Mostafa Bahaa
Adiposity, Metabolic Syndrome
Meta-analysis of Low-calorie Sweetened Beverages and Cardiometabolic Outcomes
We propose to conduct a systematic literature review and meta-analysis to assess the association of low-calorie sweetened beverages (LCSBs) on cardiometabolic outcomes in prospective cohort studies.
- Conditions
- Adiposity, Metabolic Syndrome, Type 2 Diabetes, Cardiovascular Diseases
- Trial name
- NCT04245826
- Testing
- Change in LCSBs Intake, Substitute LCSBs for SSBs or Water
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Obesity, Overweight (BMI > 25)
Impact of Protein Supplementation and Resistance Training on Body Composition, Functional Parameters, Metabolic Adaptation, and Nitrogen Balance in Adults Aged 45 Years and Older With Overweight or Obesity Receiving Incretin-based Medications
This study aim to evaluate the effects of protein supplements and resistance training on body composition, functional parameters, metabolic adaptation, and nitrogen balance in adults (aged ≥45 years) with overweight/obesity…
- Conditions
- Obesity, Overweight (BMI > 25), Weight Loss
- Trial name
- PRIME (NCT06950684)
- Testing
- Whey Protein Supplement, Resistance Training Program
- Volunteers
- 180 people
- Sponsor
- Assuta Medical Center
Overweight, Obesity
A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity
The main objectives of this trial are to investigate safety, tolerability of alternative dose titration strategies and pharmacokinetics (PK) of BI 3034701 in participants with overweight / obesity and at least one weight related…
- Trial name
- NCT07754474
- Testing
- BI 3034701
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
PCOS, Obesity
PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome
The purpose of this study was to determine whether monotherapy treatment with phosphodiesterase-4 (PDE-4) inhibitor roflumilast is more effective than treatment with glucagon-like protein 1 (GLP-1) liraglutide or treatment with…
- Trial name
- NCT02187250
- Testing
- metformin, liraglutide, roflumilast
- Where
- Slovenia
- Volunteers
- 45 people
- Sponsor
- University Medical Centre Ljubljana
Obesity
Anti-psychotic Medication (New Use) Weight Loss Study
This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have just started taking (for less than three months) certain…
- Trial name
- NCT01272752
- Testing
- IHBG-10
- Where
- United States
- Sponsor
- Avera McKennan Hospital & University Health Center
Obesity, Metabolic Syndrome
Changes in Body Composition and Metabolic Risk Parameters by Life Style Intervention.
Eligible overweight and obese persons will be randomized to one of three controlled groups: 1 group of participants is treated by health education for life style intervention only.
- Trial name
- NCT00356785
- Testing
- health education, food supplementation, food supplementation combined with physical activity program
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital Freiburg
Overweight or Obesity
A Study of ZT002 Injection in Participants With Overweight or Obesity
This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.
- Trial name
- NCT06371326
- Testing
- ZT002 Injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Overweight, Obesity
Evaluation of the Planetary Health Diet Included in a Lifestyle Program in Overweight or Obese Mexican Adults.
The EAT-Lancet Commission proposed the planetary health diet as a strategy to achieve health and sustainability goals. Currently, its effect in the treatment of obesity has not been evaluated.
- Trial name
- NCT05309044
- Testing
- Planetary Health Diet Group, Low-fat diet group, Waiting list group
- Where
- Mexico
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad de Sonora
Diabete Type 2, Obesity
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D. The study will be conducted in 4 stages.
- Trial name
- NCT06104358
- Testing
- HU6
- Where
- United States
- Sponsor
- Rivus Pharmaceuticals, Inc.